Three months into the year, Germany-based public-private fund High-Tech Gründerfonds (HTGF) has already made several new investments – including Swiss vaccine developer Amal Therapeutics, which, it is claimed, has huge potential “not only economically but also for mankind”.
Bonn-headquartered HTGF was established in 2005 to provide equity financing for technology start-ups in Germany. It now invests annually in around 40 early-stage companies globally.
“We receive around 1,300 business plans a year,” says Alexander von Frankenberg, managing director of…
